- Phase I: patient must have histologically confirmed relapsed or refractory Peripheral T-cell lymphoma (PTCL) or cutaneous T-cell Lymphoma (PTCL) as per World Health Organization (WHO) criteria. Expansion phase: patients must have histologically confirmed relapsed or refractory PTCL, relapsed or refractory CTCL, de novo PTCL, de novo tumor stage mycosis fungoides (excluding de novo plaque and patches CTCL) as per WHO criteria.